Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037467 | 0.84 | PARP1 (0.38) | PARP1ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL9109574 | 0.73 | ALDH1A1 (0.40) | PARP1ALDH1A1MAPTADORA2AKDM4E | |
| SCHEMBL7586830 | 0.68 | ALDH1A1 (0.42) | ALDH1A1ADORA2BMAPTADORA2AKDM4E | |
| SCHEMBL4961428 | 0.68 | LMNA (0.54) | PARP1ALDH1A1MAPTLMNACYP3A4 | |
| SCHEMBL643987 | 0.68 | PARP1 (0.39) | PARP1MAPTADORA2ALMNACYP3A4 | |
| SCHEMBL13984928 | 0.67 | GRIN2D (0.45) | ALDH1A1ADORA2BMAPTADORA2ALMNA | |
| SCHEMBL1229473 | 0.65 | BRD4 (0.38) | PARP1EGLN1 | |
| SCHEMBL22679184 | 0.65 | BRD4 (0.41) | ALDH1A1ADORA2BADORA2ACYP3A4KDM4E | |
| SCHEMBL4284402 | 0.65 | NR4A2 (0.44) | ALDH1A1LMNAKDM4E | |
| SCHEMBL19243050 | 0.64 | NOTUM (0.40) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658317-A1 | PROGRAMMABLE DNA PROTEOLYSIS TARGET CHIMERAS AND METHODS OF THEIR USE | Arizona Board of Regents on behalf of Arizona State University (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025015018-A1 | CONDITIONAL PROTEOLYSIS GENE SILENCING TARGETING CHIMERA AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024163374-A1 | PROGRAMMABLE DNA PROTEOLYSIS TARGET CHIMERAS AND METHODS OF THEIR USE | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-110114058-A | Improved ICE-based lipid nanoparticle formulations for delivery of MRNA | 川斯勒佰尔公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-109996889-A | Affine-oligonucleotide conjugates and application thereof | 阿布维特罗有限责任公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-109312313-A | For treating the mRNA therapy of ornithine transcarbamylase deficiency disease | 川斯勒佰尔公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109072223-A | Polymer code nucleic acid and application thereof | 川斯勒佰尔公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20180000973-A1 | AGENTS FOR USE IN THE DETECTION OF NUCLEASE ACTIVITY | HERNÁNDEZ HINCAPIÉ, Frank J. (ES) | 2018-01-04 | — | — | US | disclosed |
| EP-3209335-A1 | AGENTS FOR USE IN THE DETECTION OF NUCLEASE ACTIVITY | Hernández Hincapié, Frank J. (ES) | 2017-08-30 | — | — | EP | disclosed |
| US-9534034-B2 | Methods of modulating apoptosis by administration of relaxin agonists or antagonists | MOLECULAR MEDICINE RESEARCH INSTITUTE (US) | 2017-01-03 | — | — | US | disclosed |
| US-20030045489-A1 | Methods for modulating angiogenesis | BAYER PHARMACEUTICALS CORPORATION | 2003-03-06 | — | — | US | disclosed |
| US-20020090706-A1 | Human RRN3 and compositions and methods relating thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-07-11 | — | — | US | disclosed |
| EP-1220896-A1 | NOVEL HUMAN LIPASE PROTEINS, NUCLEIC ACIDS ENCODING THEM, AND USES OF BOTH OF THESE | MILLENIUM PHARMACEUTICALS, INC. (US) | 2002-07-10 | — | — | EP | disclosed |
| WO-2002041911-A2 | USE OF FGF-19 FOR INHIBITING ANGIOGENESIS | BAYER CORPORATION (US) | 2002-05-30 | — | — | WO | disclosed |
| WO-2002028418-A1 | METHODS OF MODULATING APOPTOSIS BY ADMINISTRATION OF RELAXIN AGONISTS OR ANTAGONISTS | MOLECULAR MEDICINE RESEARCH INSTITUTE (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-1192181-A1 | METHODS FOR MODULATING ANGIOGENESIS BY USING THE ANTI-ANGIOGENIC ANGIOTENSIN-7 AND POLYNUCLEOTIDES ENCODING THEREFOR | BAYER AG (DE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001025409-A1 | NOVEL HUMAN LIPASE PROTEINS, NUCLEIC ACIDS ENCODING THEM, AND USES OF BOTH OF THESE | MILLENIUM PHARMACEUTICALS, INCORPORATED (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2001002434-A1 | METHODS FOR MODULATING ANGIOGENESIS BY USING THE ANTI-ANGIOGENIC ANGIOTENSIN-7 AND POLYNUCLEOTIDES ENCODING THEREFOR | BAYER AG (DE) | 2001-01-11 | — | — | WO | disclosed |
| WO-1994000473-A2 | PENTAVALENT SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING STEREOSPECIFIC ALKYLPHOSPHONATES AND ARYLPHOSPHONATES | RES CORP TECHNOLOGIES INC (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000472-A2 | TRIVALENT SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING STEREOSPECIFIC ALKYLPHOSPHONATES AND ARYLPHOSPHONATES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000973-A1 | AGENTS FOR USE IN THE DETECTION OF NUCLEASE ACTIVITY | RNASE1, DNASE1, DCLRE1B | PARP1 417/4885ALDH1A1 4506/4885ADORA2B 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.